Implanet: Results of the Extraordinary General Meeting on March 25, 2019
25 Mars 2019 - 05:45PM
Business Wire
- All the resolutions were adopted by
shareholders
Regulatory News:
IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP,
FR0010458729, eligible for PEA-PME equity savings plans), a
medical technology company specializing in vertebral and
knee-surgery implants, is today announcing the results of voting at
its Extraordinary General Meeting.
Implanet’s shareholders adopted by a very substantial majority
all the resolutions supported by the Board of Directors at the
Company’s Extraordinary General Meeting, which was held at its
registered office, at the second time of calling, on March 25,
2019, with a quorum of 21.2%.
“We wish to thank our shareholders for the part they played at
the General Meeting. Their support represents a token of their deep
attachment to the Company and will help Implanet to navigate
successfully through the next stages in its expansion”, commented
Ludovic Lastennet, Chief Executive Officer of Implanet.
All the documents related to the General Meeting can be
downloaded from Implanet’s website
(https://www.Implanet-invest.com/assemblee-generale).
In addition, Implanet is reaffirming the eligibility of its
shares for PEA-PME equity savings plans, in accordance with Decree
no. 2014-283 of March 4, 2014, which lays down the eligibility
criteria for the plans. Investors can continue to hold Implanet
shares in their PEA-PME plans dedicated to investments in small and
mid-cap stocks with the same tax benefits as offered by
conventional PEA plans.
About Implanet
Founded in 2007, Implanet is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its
flagship product, the Jazz® latest-generation implant, aims to
treat spinal pathologies requiring vertebral fusion surgery.
Protected by four families of international patents, Jazz® has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States and the CE mark. Implanet
employs 38 staff and recorded 2018 sales of €6.7 million. For
further information, please visit www.implanet.com. Based near
Bordeaux in France, Implanet established a US subsidiary in Boston
in 2013.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190325005596/en/
ImplanetLudovic Lastennet, CEODavid Dieumegard, CFOTel.: +33(0)5
57 99 55 55investors@implanet.com
NewCapInvestor RelationsValentine Brouchot / Pierre LaurentTel.:
+33 (0)1 44 71 94 94implanet@newcap.eu
NewCapMedia RelationsNicolas MerigeauTel.: +33 (0)1 44 71 94
94implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024